Avecho Biotechnology Limited
AVEFFOTCHealthcare● Active
$0.00
$-0.00(-20.00%)
Market Cap$10681236
P/E Ratio—
52W High$0.0045
52W Low$0.003
Avecho Biotechnology Limited (AVEFF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVEFF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.24M | $1.29M | $0.47M | $1.21M | $0.79M |
| Cost of Revenue | $0.49M | $0.46M | $0.52M | $0.34M | $0.29M |
| Gross Profit | $0.75M | $0.83M | ($0.04M) | $0.87M | $0.51M |
| Gross Margin %(computed) | 60.70% | 64.39% | -9.25% | 72.14% | 64.00% |
| Operating Expenses | |||||
| R&D Expenses | $4.31M | $0.00M | $1.47M | $1.59M | $1.55M |
| G&A Expenses | $0.00M | $1.99M | $3.08M | $1.49M | $2.83M |
| Total Operating Expenses | $6.75M | $5.63M | $4.72M | $3.86M | $5.06M |
| Operating Income | ($6.00M) | ($4.80M) | ($4.59M) | ($3.06M) | ($4.55M) |
| Operating Margin %(computed) | -485.09% | -370.71% | -969.06% | -254.06% | -573.46% |
| Interest Income | $0.01M | $0.06M | $0.04M | $0.00M | $0.00M |
| Interest Expense | $0.46M | $0.06M | $0.02M | $0.01M | $0.01M |
| Income Before Tax | ($6.41M) | ($3.12M) | ($3.44M) | ($2.34M) | ($3.42M) |
| Income Tax Expense | ($2.00M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($4.41M) | ($3.12M) | ($3.44M) | ($2.34M) | ($3.42M) |
| Net Margin %(computed) | -356.82% | -241.27% | -725.79% | -194.20% | -430.44% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Wtd Avg Shares | 3266.77M | 3107.50M | 2268.08M | 1803.23M | 1802.27M |
| EBITDA | ($5.86M) | ($2.92M) | ($3.24M) | ($2.11M) | ($2.98M) |
| EBITDA Margin %(computed) | -474.02% | -225.66% | -684.83% | -174.63% | -375.25% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Avecho Biotechnology Limited data
About Avecho Biotechnology Limited (AVEFF) Income Statement
Avecho Biotechnology Limited (AVEFF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AVEFF reported revenue of $0.00B, gross profit of $0.00B (gross margin 60.70%), and net income of ($0.00B) — a net profit margin of -356.82%.
Frequently asked questions
AVEFF · 4 questionsAvecho Biotechnology Limited (AVEFF) reported revenue of $0.00B for 2025, down 4.4% year-over-year.
AVEFF revenueAVEFF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09